Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation: A Population-Based New Users High-Dimensional Propensity Score Matched Cohorts Study

We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. METHODS—: New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Stroke
Autors principals: Blin, Patrick, Fauchier, Laurent, Dureau-Pournin, Caroline, Sacher, Frédéric, Dallongeville, Jean, Bernard, Marie-Agnès, Lassalle, Regis, Droz-Perroteau, Cécile, Moore, Nicholas
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2019
Matèries:
Original Contributions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6727926/
https://ncbi.nlm.nih.gov/pubmed/31390972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.119.025824
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars